Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Exp Neurol. 2014 May 20;0:328–336. doi: 10.1016/j.expneurol.2014.05.014

Figure 3.

Figure 3

Intrathecal injection of CXCL1 neutralizing antibody or SB225002, a potent and selective CXCR2 antagonist, reduces CFA-induced mechanical allodynia and heat hyperalgesia at 3 days after CFA. (A, B) CXCL1 neutralizing antibody at a lower dose (4 μg) had mild effect on CFA-induced pain hypersensitivity, whereas at a higher dose (8 μg) the neutralizing antibody reversed CFA-induced mechanical allodynia (A) and heat hyperalgesia (B) for more than 24 hours. * P < 0.05, ** P < 0.01,*** P < 0.001 compared to control serum. BL, baseline. n = 6 mice/group. (C, D) SB2205002 dose-dependently attenuated CFA-induced mechanical allodynia (C) and heat hyperalgesia (D) at 3 days, with longer effect on the heat hyperalgesia. * P < 0.05; ** P < 0.01; *** P < 0.001 compared to vehicle. n = 6 mice/group.